Table 1 Patient characteristics.

From: Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool

Characteristic

Treosulfan (n = 114)

Busulfan (n = 92)

Age at SCT (years, median (range))

5.4 (0.2–18.2)

8.5 (0.4–17.8)

Sex (M/F) (%)

62/38

58/42

Diagnosis for HSCT

Beta-thalassemia (%)

35 (30.7)

6 (6.5)

Sickle cell disease (%)

20 (17.5)

0 (0)

Inborn errors of immunity (%)

32 (28.1)

10 (10.9)

Hematological malignancy (%)

18 (15.8)

63 (68.5)

Bone marrow failure (%)

9 (7.9)

13 (14.1)

Donor

MSD (%)

36 (31.6)

18 (19.6)

MUD (≥ 9/10) (%)

62 (54.4)

69 (75.0)

MMFD (haplo) (%)

16 (14.0)

5 (5.4)

Stem cell source

BM (%)

85 (74.6)

63 (68.5)

PBSC (%)

14 (12.3)

14 (15.2)

CB (%)

15 (13.2)

15 (16.3)

Conditioning

Treo-Flu-Thiotepa (%)

76 (66.7)

–

Treo-Flu (%)

36 (31.6)

–

Treo-Other (%)

2 (1.7)

–

Bu-Flu-Clo (%)

–

54 (58.7)

Bu-Flu (%)

–

28 (30.4)

Bu-Flu-Thiotepa (%)

 

7 (7.6)

Bu-Cy-Mel (%)

–

3 (3.3)

Serotherapy

ATG (%)

77 (67.5)

71 (77.2)

Alemtuzumab (%)

27 (23.7)

7 (7.6)

No (%)

10 (8.8)

14 (15.2)

GvHD prophylaxis

CsA + MTX(%)

60 (52.6)

57 (62.0)

PTCy + MMF + CsA (%)

16 (14.0)

0 (0)

CsA + Pred (%)

9 (7.9)

11 (12.0)

CsA (%)

9 (7.9)

3 (3.3)

Other (%)

13 (11.4)

16 (17.4)

None (%)

7 (6.1)

5 (5.4)

  1. MSD matched sibling donor, MUD matched unrelated donor, MMFD mismatched family donor, BM bone marrow, PBSC peripheral blood stem cells, CB cord blood, Treo treosulfan, Flu fludarabine, Thio thiotepa, Bu busulfan, Clo clofarabine, ATG Anti thymocyte globulin, GvHD Graft-versus-Host Disease, CsA Cyclosporine A, MTX methotrexate, PTCy Post-transplant cyclophosphamide, MMF mycophenolate mofetil, Pred prednisolone.
Back to article page